These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

10046 related articles for article (PubMed ID: 1122923)

  • 1. Therapeutic use of transfer factor.
    Grob PJ
    Eur J Clin Invest; 1975 Feb; 5(1):33-43. PubMed ID: 1122923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Germinal centre hyperplasia: an unfavourable immune response in recurrent malignant melanoma.
    Pihl E; Jansson B; Schwartz MA; Malahy MA; Smith JL; Gutterman JV; Hersh EM
    Pathology; 1982 Jan; 14(1):13-6. PubMed ID: 7078988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroectodermal tumor and monoclonal antibodies.
    Helson L; Weinberger C; Helson C; Lieberman P
    Am J Pediatr Hematol Oncol; 1984; 6(3):227-31. PubMed ID: 6097134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does melanin affect the low LET radiation response of Cloudman S91 mouse melanoma cell lines?
    Hill HZ; Cathcart KN; Bargellini J; Trizna Z; Hill GJ; Schallreuter KU; Wood JM
    Pigment Cell Res; 1991 Mar; 4(2):80-6. PubMed ID: 1946213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overview of melanoma vaccines and promising approaches.
    Panelli MC; Wang E; Monsurrò V; Jin P; Zavaglia K; Smith K; Ngalame Y; Marincola FM
    Curr Oncol Rep; 2004 Sep; 6(5):414-20. PubMed ID: 15291987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic potential of liposomes containing tumor necrosis factor-alpha against sensitive and resistant target cells.
    Nii A; Fan D; Fidler IJ
    J Immunother (1991); 1991 Feb; 10(1):13-9. PubMed ID: 2012796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classic in vivo cancer models: three examples of mouse models used in experimental therapeutics.
    Kruczynski A; Hill BT
    Curr Protoc Pharmacol; 2002 Feb; Chapter 5():Unit5.24. PubMed ID: 21959766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consistency of observations from echograms made centrally in the Collaborative Ocular Melanoma Study COMS Report No. 13.
    Byrne SF; Marsh MJ; Boldt HC; Green RL; Johnson RN; Wilson DJ
    Ophthalmic Epidemiol; 2002 Feb; 9(1):11-27. PubMed ID: 11815892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of the rate of death of dog tumour cells transplanted into athymic "nude" mice.
    Holmes JM
    J Comp Pathol; 1981 Oct; 91(4):511-9. PubMed ID: 6947997
    [No Abstract]   [Full Text] [Related]  

  • 10. Outcome of thick (> 4 mm) node-negative melanomas.
    Zippel DB; Shapira R; Kuchuk I; Goitein D; Winkler E; Papa MZ; Schachter J
    Isr Med Assoc J; 2009 Nov; 11(11):669-72. PubMed ID: 20108553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of the therapeutic index of interleukin-2 immunotherapy by combination with taurine in a syngeneic murine tumour model.
    Finnegan N; Toomey D; Condron C; Redmond HP; Da Costa M; Bouchier-Hayes DJ
    Ir J Med Sci; 2002; 171(2):85-8. PubMed ID: 12173896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Overexpression of the human HOXD3-antisense in melanoma cells results in decreased invasive activity].
    Okubo Y
    Hokkaido Igaku Zasshi; 2001 Jul; 76(4):239-50. PubMed ID: 11523115
    [No Abstract]   [Full Text] [Related]  

  • 13. Preparation of two dosage forms containing antitumor prostaglandin and their antitumor effect in vitro and in vivo: Lipiodol solution for i.a. administration and lipid microspheres for i.p. or i.v. administration.
    Shoji F; Masahiro N; Yoshikazu T; Masanori F
    Adv Exp Med Biol; 1997; 400B():955-61. PubMed ID: 9547652
    [No Abstract]   [Full Text] [Related]  

  • 14. Pleural mesothelioma presenting as an axillary lymph node metastasis with anemone cell appearance.
    Lloreta J; Serrano S
    Ultrastruct Pathol; 1994; 18(1-2):293-8. PubMed ID: 8191642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships.
    Su TL; Chou TC; Kim JY; Huang JT; Ciszewska G; Ren WY; Otter GM; Sirotnak FM; Watanabe KA
    J Med Chem; 1995 Aug; 38(17):3226-35. PubMed ID: 7650675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the uptake of nucleosides in cultured Harding-Passey melanoma cells by diflubenzuron.
    Mayer RT; Netter KJ; Leising HB; Schachtschabel DO
    Toxicology; 1984 Feb; 30(1):1-6. PubMed ID: 6422584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of head and neck tumors by the combination of bleomycin, methotrexate, cyclophosphamide and corticoid (author's transl)].
    Mamede RC; Mascarenhas LG
    Ann Otolaryngol Chir Cervicofac; 1980; 97(10-11):949-57. PubMed ID: 6163387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement dependence of human serum toxicity for melanoma S91 cells.
    Pace PJ; Abramoff P
    Proc Soc Exp Biol Med; 1965; 119(4):1112-7. PubMed ID: 5836017
    [No Abstract]   [Full Text] [Related]  

  • 19. The relationship of embolic homogeneity, number, size and viability to the incidence of experimental metastasis.
    Fidler IJ
    Eur J Cancer (1965); 1973 Mar; 9(3):223-7. PubMed ID: 4787857
    [No Abstract]   [Full Text] [Related]  

  • 20. [On the biosynthesis and structure of animal melanin. In vivo studies with tritium and 14C-labelled dopa on the mouse Harding-Passey melanoma].
    Hempel K
    Z Naturforsch B; 1967 Feb; 22(2):173-80. PubMed ID: 4384714
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 503.